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C5a, one of the most potent inﬂammatory peptides, induces its inﬂammatory functions by interacting with C5a receptor (C5aR)
that belongs to the rhodopsin family of seven-transmembrane G protein-coupled receptors. C5a/C5aR signaling has been impli-
cated in the pathogenesis of many inﬂammatory and immunological diseases such as sepsis and acute lung injury. Widespread
upregulation of C5aR has been seen at both the protein level and transcriptional level under pathological conditions. Here, we
show that C5aR gene expression can be speciﬁcally suppressed by siRNA, both in vitro and in vivo. A panel of chemically siRNA
oligonucleotides was ﬁrst synthesized to identify the functional siRNA sequences. The short hairpin RNAs (shRNAs) were also
designed, cloned, and tested for the silencing eﬀects in C5aR transfected cells. The eﬀective shRNA expression cassettes were then
transferredtoanadenovirusDNAvector.ShRNA-expressingadenoviruseswereintratracheallyadministeredintomouselung,and
a signiﬁcant in vivo silencing of C5aR was obtained four days after administration. Thus, C5aR shRNA-expressing adenoviruses
appear to be an alternative strategy for the treatment of complement-induced disorders.
Copyright © 2006 Lei Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
The complement system was initially identiﬁed as an impor-
tant innate immune mechanism of host defense to eradi-
cate microbial pathogens. Recently, complement activation
has been implicated in the pathogenesis of many inﬂam-
matory and immunological diseases, including sepsis [1],
acute respiratory distress syndrome [2], rheumatoid arthritis
[3], glomerulonephritis [4], multiple sclerosis [5], ischemia-
reperfusion injury [6], and asthma [7]. Complement acti-
vation exerts its harmful roles through the generation of
complement protein split products, especially C3a and C5a
(also known as anaphylatoxins). C5a induces its inﬂamma-
tory functions by interacting with C5aR that belongs to
the rhodopsin family of seven-transmembrane G protein-
coupled receptors [8–10]. Traditionally, C5aR expression
was thought to be present only on hemopoietic cells, bone
marrow cells [11], neutrophils [12], monocytes [13], and
eosinophils [14]. However, recent studies have demonstrated
the presence of C5aR on nonmyeloid cells, including cells in
human lung and liver [15–17],rodenttypeIIalveolarepithe-
lial cells [18], astrocytes [19], kidney tubular epithelial cells
[20], mesangial cells [21], and hepatocyte-derived cell lines
[22, 23]. Widespread upregulation of C5aR has been seen in
organs (heart, liver, lungs, kidneys) from septic animals [24].
Due to the detrimental eﬀects of complement activa-
tion under pathologic conditions, interventions aimed at
blocking C5a/C5aR signaling represent promising targets for
therapeutic treatment in the inﬂammatory disorders. Pep-
tide antagonist (C5aRa) to the C5aR markedly reduced the
lung permeability index (extravascular leakage of albumin)
in mice after intrapulmonary deposition of IgG immune
complexes [25]. C5aRa treatment substantially reduced I/R-
induced pathological markers [26, 27]. In addition, mice in-
jected at the start of CLP with a blocking antibody to C5aR
showed dramatically improved survival [24].
RNA interference (RNAi) is an emerging technology that
speciﬁcally inhibits target gene expression in vitro and in
vivo. Tuschl and colleagues demonstrated that exogenously
introduced short (19–23nt) synthetic RNA oligonucleotides
can silence genes in somatic cells without activating non-
speciﬁc suppression by dsRNA-dependent protein kinases
[28]. Successful gene silencing has been achieved in vivo by
intravenous injection of siRNA oligos in a large volume of
saline solution [29–31] or by injecting smaller volumes of
siRNAs that are packaged in cationic liposomes [32]. How-
ever, these strategies are limited by the in vivo stability of
siRNAmoleculesandtheeﬃciencywithwhichtheyaretaken
up by target cells and tissues. DNA vector-based siRNA ex-
pression system would facilitate transfection experiments in2 Journal of Biomedicine and Biotechnology
cell cultures, and allow the use of transgenic or viral deliv-
ery systems [33–36]. Several viral vectors have been used
to induce RNAi silencing in cultured cells and in exper-
imental animals, including lentivirus [37, 38], retrovirus
[33], adenovirus [39, 40] and adeovirus-associated viruses
(AAV) [41, 42]. Adenoviruses can infect a wide range of
cells and have been shown to silence gene expression in vivo
[39, 43, 44]. In this study, we demonstrated that systemic ap-
plication of an adenovirus expressed siRNA can speciﬁcally
inhibit C5aR gene expression in vivo.
MATERIALS AND METHODS
Cellsandantibodies
Mouse alveolar macrophages (MHS cell line) were pur-
chased from ATCC and was cultured in RPMI1640 medium
(Life Technologies) supplemented with 10% fetal calf
serum as well as 2mM L-glutamine, 4.5g/L glucose, 10mM
HEPES, 1.0mM sodium pyruvate, penicillin (100U/ml) and
streptomycin (100µg/ml), and 0.05mM 2-mercaptoethanol.
H E K 2 9 3c e l lw a sc u l t u r e di nD M E Mm e d i u m( L i f eT e c h -
nologies) supplemented with 10% fetal calf serum.
Anti-mouse C5aR polyclonal antibody was generated
againsta37aapeptidespanningtheNterminusofthemouse
C5aR (MDPIDNSSFEINYDHYGTMDPNIPADGIHLPKR-
QPGDC) [45]. The antipeptide speciﬁc Ab was puriﬁed by
aﬃnity chromatography using the synthetic peptide coupled
to cyanogen bromide-activated Sepharose 4B (Amersham
Pharmacia Biotech, Piscataway, NJ). HA antibody (12CA5)
was obtained from BABCO (Berkeley Antibody Company).
Cecalligationpuncture-inducedsepsis
C57BL/6 male mice (6 to 8wk of age weighing 25–30g; Jack-
son Laboratories, Bar Harbor, ME) were used in all experi-
ments. Mice were anesthetized with ketamine. A 1cm long
midline incision was made to expose the cecum and adjoin
the intestine. With a 4–0 silk suture, the cecum was tightly
ligated below the ileocecal valve without causing bowel ob-
struction.Thececumwaspuncturedthroughwitha21gauge
needle and gently squeezed to extrude luminal contents, en-
suring patency of the two puncture holes. The abdominal
incision was then closed with a 4–0 nylon suture and skin
metallic clips (Ethicon, Somerville, NY). Sham-operated an-
imals underwent the same procedure except for ligation and
puncture of the cecum.
CloningofmouseC5aR
According to the mouse C5aR sequence [46], two primers
(forward primer: 5 -CGG AAT TCC GAT GGA CCC CAT
AGATAACAGC-3 ;reverseprimer:5 -GAA GAT CTT CTA
CAC CGC CTG ACT CTT CCG-3 ) were designed to am-
plify mouse C5aR from mouse liver RNA using reverse
transcription-polymerasechainreaction.PCRproductswere
digested with EcoR I and Bgl II and then cloned into pCMV-
HA, a mammalian expression vector that contains the
hemagglutinin epitope (PYDVPDYA).
Table 1: Sequences and locations of siRNA oligos.
No. Sense sequences (5 − > 3 ) Locations
1 CGCCAUCUGGUUUCUGAAUd(TT) 210
2 CUACUGGUACUUUGAUGCCd(TT) 297
3 ACAUCUGCUACACCUUCCUd(TT) 656
4 CCCUAUCAUCUACGUCAUGd(TT) 888
siRNAoligos
The 21nt sense and antisense siRNA oligomers targeting
against mouse C5aR mRNA were designed and synthesized
by Qiagen. Their locations and sequences are shown in
Table 1 (onlythesensesequencesareshown).Theoligoswere
numbered based on the nucleotide position within the cod-
ing region of mouse C5aR sequence. Sense and antisense oli-
gos were annealed in HEPES buﬀer (100mM potassium ac-
etate, 30mM HEPES-KOH, 2mM magnesium acetate, pH
7.4) to obtain siRNA duplexes. Rhodamine labeled control
(nonsilencing) siRNA was also purchased from Qiagen.
Celltransfectionandwesternblot
For MHS cell transfection, cells were plated in 6-well plates
(8 ×105/well) and transfected with 6µ lo fT r a n s I T - T K O
(Mirus) and 30pmol of siRNA duplexes. Silencing eﬀects
were detected by semiquantitative RT-PCR two days af-
ter transfection. For HEK293 cell transfection, cells plated
in 35mm dishes (5 × 105 cells/dish) were transfected
with HA-tagged C5aR using Lipofectamine 2000(Invitro-
gen). Two days after transfection, cells were placed in ly-
sis buﬀer containing 50mM HEPES, pH 7.4, 1% Triton X-
100, 2mM MgCl2, 150mM NaCl, 1mM dithiothreitol, and
1mM PMSF. Thirty microliters of the whole cell lysates were
electrophoresed in 10% SDS-PAGE and then transferred to
a nitrocellulose membrane. Nonspeciﬁc binding sites were
blockedwithTBST(40mMTris-HCl,pH7.4,300mMNaCl,
0.1% Tween 20), containing 5% nonfat dry milk for 1 hour
at room temperature. The membrane was then incubated
with anti-mouse C5aR serum (1:500 dilution) overnight at
4◦C. After three washes in TBST, the membrane was then
incubated in a 1:10000 dilution of horseradish peroxidase-
conjugated donkey anti-rabbit IgG (Amersham Pharma-
cia). The membrane was developed by enhance chemilu-
minescence according to the protocol of the manufacturer
(Amersham Pharmacia).
DetectionofC5aRmRNAbysemiquantitativeRT-PCR
Total RNA was isolated from cells or lung tissue with the
Trizol reagent according to the manufacturer’s instructions
(Invitrogen). Digestion of any contaminating DNA was
achieved by treatment of samples with RQI RNase-free
DNase (Promega). RT-PCR was performed with 1µgo ft o -
tal RNA using the one-step RT-PCR system (Invitrogen)
according to the protocol of the manufacturer. Primers forLei Sun et al 3
Table 2: Sequences and locations of short hairpin RNAs (note: “G” indicates an extra nucleotide added to the target sequence).
No. Hairpin sequences (5 − > 3 ) Locations
1g a t c c GCTACTGGTACTTTGATGCttcaagagaa(ASb)TTTTTg 300
2 gatccGCCCATCTGGTGTCAGAAGttcaagagaa(ASb)TTTTTg 420
3 gatccGTGTACCGGGAGGCATAAttcaagagaa(ASb)TTTTTg 517
4g a t c c GACATCTGCTACACCTTCCTttcaagagaa(ASb)TTTTTg 656
5 gatccGAGGGTGGAGAAGCTGAACttcaagagaa(ASb)TTTTTg 831
6g a t c c GCCCTATCATCTACGTCATGttcaagagaa(ASb)TTTTTg 888
a hairpin loop sequence.
b antisense sequence.
C5aR were
(i) forward primer: 5 -GTTGCAGCCCTTATCATCTA-
C-3 ,
(ii) reverse primer: 5 -TTCCGGGTTGAGGTGTCGTCT-
G-3 .
The primers were designed for a 908bp DNA fragment
ampliﬁcation (nucleotides 112-1019). The primers for the
“housekeeping” gene GAPDH were
(i) forward primer: 5 -ACCACCATGGAGAAGGCTGC-
3 ,
(ii) reverse primer: 5 -CTCAGTGTAGCCCAGGATGC-
3 .
After a reverse transcription step for 30min at 50◦C, 25–
35 cycles were used for ampliﬁcation with a melting temper-
ature of 94◦C, an annealing temperature of 60◦C ,a n da ne x -
tending temperature of 72◦C, each for 30 seconds, followed
byaﬁnalextension at72◦Cfor7min.R T -PCRpr oductswer e
conﬁrmed by electrophoresis of samples in 1% agarose gel.
To ensure that DNA was detected at the linear part of the
ampliﬁcationcurves,PCRwasperformedwithdiﬀerentcycle
numbers for C5aR and GAPDH primers. Thirty cycles were
used for C5aR ampliﬁcation in CLP mice, and thirty-two cy-
cleswereusedincontrolmice.TwentyﬁvecyclesforGAPDH
were found to be in the linear range of PCR ampliﬁcations.
Immunocytochemistryandconfocalmicroscopy
HEK293 cells were plated on glass bottom 6-well plates (no.
1 thickness coverslips). Two days after transfection, cells
were ﬁxed in paraformaldehyde. Fluorescence microscopy
was performed as previously described [47]. HA-tagged
C5aR was visualized with the aﬃnity puriﬁed anti-mouse
C5aR antibody (1:500 dilutions) and goat anti-rabbit Alexa
568 (Molecular Probe) secondary antibody (1:1000 dilu-
tions) in the lissamine-rhodamine channel. Cells were im-
aged on a LSM 510 laser scanning confocal microscope
(Zeiss, Oberkochen, Germany) with a 63 × water lens.
PlasmidsexpressingshorthairpinRNAs
Vectors that express C5aR short hairpin RNAs (shRNAs)
under the control of U6 promoter were constructed by in-
serting pairs of annealed DNA oligonucleotides into the
linearized RNAi-Ready pSIREN-DNR-DsRed-Express Vec-
tor (BD knockout adenoviral system 2) between the BamH
I and EcoR I sites. Sequences and locations of shRNAs are
shown in Table 2 (only the top strands are shown).
GenerationofsiRNA-expressingadenoviruses
U6-driven shRNA cassettes and the CMV-driven DsRed ex-
pression cassette in pSIREN-DNR-DsRed donor vector ware
transferred to the adenoviral acceptor vector pLP-Adeno-X-
PRLS by cre-loxP mediated recombination according to the
protocol of the manufacturer. HEK293 cells were transfected
with Pac I-digested adenoviral DNA using lipofectamine
2000. One week after transfection, cytopathic eﬀect (CPE)
was detected and cells were spun down and lysed in 500µl
PBS with three consecutive freeze-thaw cycles. Supernatants
containing infectious adenoviruses were ampliﬁed twice by
infecting larger scale of HEK293 cells. Viruses were puriﬁed
by column (Puresyn, Inc) and concentrated by YM-50 cen-
tricon (Millipore). Titers of the viruses were determined by
Adeno-X rapid titer kit (BD clontech).
Isolationofperitonealmacrophagesand
adenovirusinfection
Macrophages were isolated from the peritoneal cavities of
4- to 6-week-old C57BL/6 mice 4 days after intraperi-
toneal injection of 0.5ml 3% thioglycollate, yielding ≥ 95%
macrophages as demonstrated by cytospin and diﬀerential
stain analysis. The cells were seeded at a density of 2 ×
106 cells/ml and plated into 6-well plates at 2ml/well [48]i n
the same culture medium as MHS cells.
MHS cells and peritoneal macrophages plated in 6-well
plates were infected with 100- to 2000-MOI of adenoviruses
in a volume of 150µl of culture medium for one-hour. Dur-
ing the one hour incubation, plates were shaked occasionally
ata15mininterval.Cellswerechangedto2mlfreshmedium
aftertheincubationandculturedforanothertwodaysforthe
examination of silencing eﬀects.
Adenovirus-mediatedsiRNAdeliveryinanimals
Eight- to 10-week-old C57BL/6 mice (weighing 25–30g)
were used in this study. The 50µl viral suspensions with a4 Journal of Biomedicine and Biotechnology
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Figure 1:ScreeningoffunctionalmouseC5aRsiRNAoligosinMHScells.MHScellsin6-wellplatesweretransfectedwith30pmolofcontrol
siRNA and four C5aR siRNA oligos using Mirus TransIT-TKO transfection reagent. (a) Eight hours after transfection, cells transfected with
Rhodamine-labeled control siRNA were plated on glass-bottom plate and washed twice with phenol-red-free medium and subjected to
confocalmicroscopyanalysis(Zeiss).Thetransfectedcellswerevisualizedbyredﬂuorescence(left).(b)TotalRNAextractedfromtransfected
MHScellswasquantiﬁedforC5aRmRNAexpressionbysemiquantitativeone-stepRT-PCR(upperpanel).GAPDHwasusedasendogenous
control (lower panel).
dosage of 1 × 109 plaque-forming units (pfu) were injected
intracheally into mouse lungs. Four days after the injection,
mouse lung were extensively ﬂushed with DPBS, and frozen
in liquid nitrogen. The 2ml Trizol reagent was added into
one lung for RNA isolation procedure.
RESULTS AND DISCUSSION
siRNAduplexesefﬁcientlyinhibitedendogenous
C5aRinMHScells
The 21- to 23-nucleotide siRNAs were generated by ribonu-
clease III through cleavage of longer dsRNAs. They have
been shown to act as the mediators of post-transcriptional
gene silencing in cells and animals [49, 50]. For the initial
screening of the functional siRNA sequences of mouse C5aR,
we used synthesized 21-nucleotide siRNA duplexes with 3 -
(dTT) overhangs (Table 1) to transiently transfect MHS cell,
a cell line that expresses C5aR mRNA endogenously.
Similar to other macrophages, none of the standard tran-
fectionmethods(e.g.,calciumphosphate,lipid,orelectropo-
ration)caneﬃcientlytransferDNAplasmidsintoMHScells.
As a minimum, seventy percentage transfection eﬃciency is
required to study the silencing eﬀects. We used rhodamine-
labeled control siRNA to determine the transfection eﬃ-
ciency.DiﬀerentfromlargerDNAplasmids,shortsiRNAoli-
gos could be eﬃciently transferred into MHS cells by a lipid-
mediated method (TransIT-TKO). All of the cells showed
red ﬂuorescence eight hours after transfection (Figure 1(a)).
No ﬂuorescence was observed for the control cells without
TransIT-TKO reagent (data not shown). To conﬁrm that
these oligos actually entered the cells, a Z-stack protocol of
confocal microscopy was performed and the scanning results
conﬁrmed the cytosolic localization of the ﬂuorescence-
labeled siRNA.
All four synthesized siRNA duplexes showed silencing
eﬀects on the endogenous C5aR expression as examined
by semiquantitative RT-PCR (Figure 1(b)). SiC5aR-210 and
siC5aR-297hadmoderateinhibitioneﬀects,whereassiC5aR-
656 and siC5aR-888 suppressed 90 percentage of the endoge-
nous gene. No silencing eﬀects were observed for the control
siRNA (scrambled sequences). The speciﬁcity of these siRNA
oligos was veriﬁed by BLAST search against the gene bank.
Cotransfection of siRNA duplexes inhibits C5aR protein
expressioninHEK293cells
C5aR is a member of the seven transmembrane receptor
superfamily and is ubiquitously expressed on neutrophils,
macrophages, thymocytes, epithelial, and endothelial cells.
However, in vitro cultured cell lines have very low or non-
detectable expression of the receptor. To determine if these
siRNA duplexes could also suppress C5aR protein expres-
sion, full-length mouse C5aR cDNA was cloned into a HA-
tagged mammalian expression vector and transfected into
HEK293 cells. Immunocytochemistry analysis showed that
this C5aR construct showed a cortical pattern of expression
on the membranes of HEK293 cells (Figure 2(a)). Western-
blot analysis using anti-mouse C5aR antibody revealed a
∼ 45kDa band, which is consistent to the size of the receptor
expressed in tissues and primary cells (Figure 2(b))[ 51].
In the cotransfection experiment, 0.8µg C5aR plasmid
was transfected with 40pmol of control siRNA or the C5aR-
siRNAs. Two days after transfection, these cell lysates were
analyzed by Western blot. Compared to control group, both
siRNAs (siC5aR-656 and siC5aR-888) could signiﬁcantlyLei Sun et al 5
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Figure 2: Oligo siRNA inhibition of C5aR protein expression in HEK293 cells. HEK293 cells were cotransfected with HA-tagged C5aR
plasmid, control siRNA, or C5aR siRNA oligos. (a) Forty-eight hours after transfection, transfected cells were ﬁxed in paraformaldehyde and
stainedwiththeanti-mouseC5aRprimaryantibodyandgoatanti-rabbitAlexa568secondaryantibody.ExpressionandlocalizationofC5aR
were visualized by confocal microscope under lissamine-rhodamine channel (Zeiss). (b) Cell lysates from transfected cells were subjected to
Western-blot analysis using anti-mouse C5aR antibody (1:500).
inhibit the protein expression of C5aR in HEK293 cells (Fi-
gure 2(b)).
HairpinRNAconstructsinhibitC5aRexpression
Based on the identiﬁed C5aR siRNA oligonucleotide se-
quences, we designed short hairpin RNAs (shC5aR-656 and
shC5aR-888) according to the design rules suggested by the
manufacturer(BDPharMingen)andinsertedthemintoaU6
promoter-driven shRNA expression donor vector, pSiren-
DNR-dsRed. For the most eﬃcient transcription initiation
of RNA polymerase III, an extra “G” was added at the 5 
end of the sense sequence (Table 2). Sense- and antisense nu-
cleotides were separated by a 9nt spacer and ﬁve consecutive
Ts were added at the 3  end for the termination of short RNA
transcripts.
To evaluate the silencing eﬀects of these short hairpins, a
1:10 (HA-C5aR to hairpin RNA) ratio of plasmids was used
for the cotransfection experiment in HEK293 cells. A lu-
ciferase short hairpin construct pSiren-shLuc served as neg-
ative control. Unexpectedly, neither one of the C5aR hairpin
constructs (pSiren-shC5aR-888 and pSiren-shC5aR-656) ef-
ﬁciently inhibited C5aR expression (Figure 3).
Diﬀerent from synthesized siRNA oligos, the eﬀects of
DNA vector-based hairpin RNAs are regulated by multiple
components. Target sequence selection is an important com-
ponent, while other factors such as the transcription eﬃ-
ciency, the cleavage eﬃciency of hairpin RNA into siRNA by
Dicer [33], and the subcellular localization of the short tran-
script [52], can also aﬀect the eﬃcacy of a hairpin RNA. To
select an eﬀective hairpin RNA structure that could be used
for our in vivo adenoviral delivery, four additional plas-
mids, pSiren-shC5aR-300, pSiren-shC5aR-420, pSiren-shC-
5aR-517 and pSiren-shC5aR-831 were constructed. pSiren-
shC5aR-831 (third bar) and pSiren-shC5aR-517 (ﬁfth bar)
strongly inhibited C5aR expression in HEK293 cells, while
pSiren-shC5aR-420 (sixth bar) and pSiren-shC5aR-300 (sev-
enthbar)hadlittleinhibitoryeﬀects(Figure3).Noextra“G”
was added to pSiren-shC5aR-420, -517 and -831 as the target
sequence itself start with a “G”. An extra “G”w a sa d d e dt o
pSiren-shC5aR-300 (Table 2).
Invitroandinvivosilencingeffectsof
adenovirus-expressedsiRNA
pSiren-DNR-DsRed is an intermediate vector of adenoviral
DNA. After we identiﬁed two functional shRNAs (C5aR-517
and C5aR-831), the U6 promoter and the hairpin cassette in
the donor vector were transferred to a promoterless aden-
oviral acceptor vector by cre-loxp mediated recombination.
The adenoviral DNAs were then transfected into HEK293
cellstoproduceinfectiousviruses.Twoadenoviruses(adeno-
shC5aR-517 and adeno-shC5aR-831) and one control virus
(adeno-shLuc) were generated for in vivo gene silencing.
Macrophages that express C5aR endogenously were used
to test the silencing eﬀects of these viruses. However, these6 Journal of Biomedicine and Biotechnology
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Figure 3: Silencing eﬀects of plasmid-derived short hairpin RNAs.
HEK293 cells in 6-well plates were transfected with 4µg of a 10:1
mix of pSIREN-DNR-DsRed-shRNA to HA-tagged C5aR together
with 0.3µg gfp plasmid. Forty-eight hours after transfection, cell
lysates were analyzed by Western-bloting for HA (upper panel).
Expression of gfp showed equal transfection eﬃciency. The bot-
tom panel showed the quantitative densitometric analysis of bands
shownintheupperpanel.Thepercentageofinhibitionwasnormal-
ized to control cells transfected with luciferase-shRNA. Averages are
derived from 3 to 5 independent experiments (standard deviations
are indicated).
cells do not express coxsackie receptor [53, 54] and they
internalize adenovirus about 100- to 1000-fold less than
receptor-expressing cells, such as epithelial cells [55]. To
identify an optimal infection condition, we tested a range of
infectious units (100, 500, 1000, and 2000MOI) and found
that ∼ 80% of the cells could be infected (as shown by the
DsRed marker in the adenoviral DNA) at 2000MOI (Figure
4), whereas less than half the cells were infected at 1000MOI
(data not shown). In addition to the high infectious units,
we also used a low volume of medium during the incu-
bation to enhance other virion uptake pathways (endocy-
tosis or phagocytosis). C5aR mRNA expression in infected
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Figure 4: In vitro silencing by siRNA-expressing adenovirus. Both
MHScellandperitonealmacrophageswereinfectedwith2000MOI
of adenovirus. (a) Sixty hours after infection, expression of dsRed
protein inthecells was visualized byﬂuorescence microscope. Virus
infection eﬃciency was examined by comparing the ﬂuorescence
images(left)andthebrightﬁeldimages(right).(b)Silencingeﬀects
of adenovirus-expressed siRNAs were examined by one-step RT-
PCR as described in Material and Method. Adeno-luciferase siRNA
was used as control.
MHScellswereexaminedbysemiquantitativeRT-PCR.Both
adeno-shC5aR-517 and adeno-shC5aR-831 eﬀectively inhib-
ited endogenously expressed C5aR and the inhibition eﬀect
of adeno-shC5aR-831 appeared to be stronger (Figure 4(b)).
To evaluate the ability of virally expressed siRNAs to di-
minish target gene in vivo, mice were injected intratracheally
with1×109 plaque-formingunit(pfu)infectiousunitsofre-
combinant adenovirus expressing shC5aR-831 or the control
virus adeno-shLuc. Four days after infection, RNAs were iso-
latedfrommouselungsandsubjectedtoRT-PCRanalysis.As
shown in Figure 5(b), the luciferase control virus infection
did not change C5aR expression in the lung tissue. However,Lei Sun et al 7
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Figure 5: In vivo silencing by adenovirus delivey of siRNA. (a)
The predicted shRNA transcript from the adenovirus vector and
the expected Dicer processing products in vivo. Semiquantitative
RT-PCR analysis with whole lung RNAs from control (b) and sep-
tic mice (c) showed the decreased C5aR expression in mice in-
fected with C5aR-siRNA adenovirus. Luciferase-siRNA-adenovirus
infected lungs were used as controls.
adeno-shC5aR-831eﬀectively inhibited C5aR expression in
thelungtissue.Totesttheeﬀectofadeno-shC5aR-831indis-
ease condition, sepsis was induced by CLP in mice that had
received adenovirus for four days. Twenty four hours after
CLP, RNAs from lungs were analyzed for C5aR and GAPDH
expression. As shown in Figure 5(c), the inhibitory eﬀect of
adeno-shC5aR-831 is still eﬀective under sepsis condition.
ThesedataindicatethatcomplementreceptorC5aRcouldbe
suppressedinvivobyanadenovirus-mediatedsiRNAknock-
down strategy under both normal and disease conditions.
RNA interference is a powerful tool to silence gene
expression post-transcriptionally. Diﬀerent from gene knock
out, the inhibition eﬃciency of siRNAs could vary dramati-
cally by employing a diﬀerent delivery method and sequence
design strategy of siRNA oligonucleotides or short hair-
pins. In this study, it is noted that the vector-based siRNA
sequences could not be simply derived from chemically syn-
thesized oligo sequences. It may be due to the fact that the
functionality of shRNAs depends on more complicated in-
tracellular mechanisms. In fact, none of the current design
rules guarantee an eﬀective siRNA and a functional siRNA
can only be identiﬁed experimentally. Another important
factor that aﬀects the application of siRNA is the eﬃciency
and the eﬀectiveness of delivery routes. Here we demon-
strated the intratracheal administration of siRNA-expressing
adenovirus that could eﬃciently knock down C5aR expres-
sion. Thus, C5aR siRNA-expressing adenovirus shall not
only serve as a useful tool for studying the mechanisms of
complement activation in inﬂammation, but may also have
important therapeutic applications.
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